AML
Conditions
Brief summary
In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The control group receive high-dose cytarabine(HDAC) regimen while the experimental group receive high dose of cytarabine plus tretinoin(ATRA) and arsenic trioxide(ATO) treatment.The safety and efficacy of ATRA and ATO is evaluated.
Detailed description
In this open-label, randomized, prospective clinical trial, NPM1- mutated AML patients who have reached CR are randomized into two groups. In experimental group, patients receive cytarabine at a dose of 3g/㎡/d on the first, third and fifth day, ATRA at a dose of 30mg/㎡/d on day 1-14 and ATO at a dose of 0.15mg/kg/d (maximum, 10mg/d) on day 1-14. Patients in control group only receive high dose of cytarabine. The safety and efficacy of ATRA plus ATO regimen is evaluated.The primary outcome is relapse-free survival rate after treatment.
Interventions
DRUGCytarabine
Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
DRUGall-trans retinoic acid
ATRA at a dose of 30mg/㎡/d on day 1-14.
DRUGArsenic Trioxide
ATO at a dose of 10mg/d on day 1-14
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Age of 14 to 55 years old; 2. Patients that meet the diagnostic criteria(WHO 2008 criteria) of AML (except APL subtypes) and with NPM1-mutated. 3. Reached CR after induction regimen. 4. ECOG score of ≤ 2; 5. Patients with eligible laboratory examination including liver,renal and heart function. 6. Adult patients are willing to participate in the study and sign the informed consent by themselves or by their immediate family. Patients under 18 years old willing to participate should have their legal guardians sign the informed consent.
Exclusion criteria
1. Secondary leukemia. 2. Patients had other tumor at active stage or had received radiotherapy or chemotherapy in the last 6 months due to other tumor. 3. Patients with other blood diseases(for example, haemophiliacs) are excluded.However, patients with abnormal blood count, but with undiagnosed MDS or MPD patients are included. 4. Acute panmyelosis with myelofibrosis and myeloid sarcoma patients; 5. With BCR-ABL fusion gene; 6. Pregnant or lactating women; 7. With ineligible renal or liver function; 8. With active cardiovascular disease; 9. Severe infection disease including uncured tuberculosis pulmonary aspergillosis; 10. AIDS; 11. Patients had central nervous system involvement when they were diagnosed as AML. 12. Patients with epilepsy or dementia or other mental disease who couldn't understand or follow the research. 13. Drugs, medical, mental or social situation may distract patients from following the research or being evaluated the results. 14. Patients with other factors which were considered unsuitable to participate in the study by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse-Free Survival Rate (RFS) | Within 5 years after randomization | RFS is defined as the time from the date of complete remission (CR) after entry in this trial until the date of documented relapse or death for NPM1 mutated leukemia patients who achieve CR. |
Secondary
| Measure | Time frame |
|---|---|
| Non-relapse Mortality | through treatment completion, an average of 5 months |
| Overall Survival Rate (OS) | Within 5 years after randomization |
| Cumulative incidence of relapse | Within 5 years after randomization |
Countries
China
Outcome results
None listed